Incretin-based therapies in type 2 diabetes: A review of clinical results

被引:20
|
作者
Bosi, Emanuele [1 ]
Lucotti, Pietro
Setola, Emanuela
Monti, Lucilla
Piatti, Pier Marco
机构
[1] Ist Sci San Raffaele, Diabet & Endocrinol Unit, Dept Internal Med, I-20132 Milan, Italy
关键词
GLP-1; analogues; DPP-4; inhibitors; Exenatide; Sitagliptin; Vidagliptin; Diabetes mellitus;
D O I
10.1016/j.diabres.2008.10.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
GLP-1 analogues (incretin mimetics) and DPP-4 inhibitors (incretin enhancers) represent new classes of anti-diabetic agents for the treatment of type 2 diabetes. The efficacy and safety of the incretin mimetic exenatide and of the DPP-4 inhibitors, sitagliptin and vildagliptin, have been clearly demonstrated by a very large number of clinical trials. Efficacy was demonstrated in terms of reduction of HbA1c, fasting and postprandial glucose. Moreover, exenatide showed a favourable effect on weight, while DPP-4 inhibitors were neutral with respect to this outcome. The low rate of hypoglycemic events seen in all studies confirms the glucose dependent action of incretins. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:S102 / S107
页数:6
相关论文
共 50 条
  • [1] Pharmacological management of type 2 diabetes: the potential of incretin-based therapies
    Charbonnel, B.
    Cariou, B.
    DIABETES OBESITY & METABOLISM, 2011, 13 (02) : 99 - 117
  • [2] The evolving place of incretin-based therapies in type 2 diabetes
    Gallwitz, Baptist
    PEDIATRIC NEPHROLOGY, 2010, 25 (07) : 1207 - 1217
  • [3] Comparison of efficacy between incretin-based therapies for type 2 diabetes mellitus
    Nisal, Kaustubh
    Kela, Ram
    Khunti, Kamlesh
    Davies, Melanie J.
    BMC MEDICINE, 2012, 10
  • [4] Incretin-based Therapies for Type 2 Diabetes Mellitus: Effects on Insulin Resistance
    Grigoropoulou, Pinelopi
    Eleftheriadou, Ioanna
    Zoupas, Christos
    Diamanti-Kandarakis, Evanthia
    Tentolouris, Nicholas
    CURRENT DIABETES REVIEWS, 2013, 9 (05) : 412 - 417
  • [5] Which place for incretin-based therapies with type 2 diabetes?
    Halbron, Dr Marine
    CORRESPONDANCES EN METABOLISMES HORMONES DIABETES ET NUTRITION, 2010, 14 (03): : 61 - 63
  • [6] Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction
    Russell, Sheldon
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2013, 35 (02) : 159 - 172
  • [7] Focus on Incretin-Based Therapies: Targeting the Core Defects of Type 2 Diabetes
    Jellinger, Paul S.
    POSTGRADUATE MEDICINE, 2011, 123 (01) : 53 - 65
  • [8] Safety of incretin-based therapies for type 2 diabetes
    Davis, Timothy M. E.
    MEDICAL JOURNAL OF AUSTRALIA, 2011, 195 (06) : 312 - 313
  • [9] Incretin-Based Therapies in Patients with Type 2 Diabetes
    Freeman, Jeffrey S.
    CURRENT DRUG THERAPY, 2010, 5 (02) : 75 - 85
  • [10] Incretin-Based Therapies: Review of Current Clinical Trial Data
    Peters, Anne
    AMERICAN JOURNAL OF MEDICINE, 2010, 123 : S28 - S37